FDA Approval Round Up: Keytruda, Opdivo Add Claims

Cancer supplements took center stage for US FDA this week, but OptiNose Inc.'s corticosteroid Xhance also took a bow.

ApproveOnKeyboard_1200x675

Merck & Co. Inc.'s Keytruda (pembrolizumab) reached double digits for FDA-approved indications, with the agency most recently backing the programmed-death receptor for the treatment of gastric cancer.

Keytruda specifically gained accelerated approval Sept. 22 for the treatment of patients with recurrent locally advanced or metastatic gastric or...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Product Reviews

Complete Response Letters: Will Industry Fight US FDA’s Disclosure Plans?

 
• By 

The FDA's release of CRLs for unapproved products could bring a court challenge, but for now, sponsors should expect all past and future letters will be made public, experts said.

Pink Sheet Podcast: US FDA Drops Offit From Adcom, Releases Unapproved Product CRLs

Pink Sheet editors discuss the recent departure of a noted vaccine expert and many others from FDA advisory committee rosters, as well as the details and potential impact of the FDA’s release of dozens of complete response letters for unapproved products.

89 Complete Response Letters For Unapproved Drugs, One Huge Leap For US FDA Transparency

 

The US FDA’s unprecedented publication of 89 recent CRLs for unapproved products comes with a promise to release future letters more promptly.

New EU Filings

 

Insulin efsitora alfa, Eli Lilly’s once-weekly, subcutaneous treatment for type 2 diabetes, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

More from Pink Sheet

EU Critical Medicines Act May Include Investigational Products & Mandatory Redistribution Measure

 

The inclusion of investigational drugs in the Critical Medicines Act and new provisions on stockpiling are among the raft of amendments the European Parliament has made to the draft legislation.

EU HTA Regulation: Key Gaps Identified In Support For Small Companies And Experts

 

A meeting between the European Commission and industry stakeholders has revealed several areas of importance and lessons learned in relation to the EU Health Technology Assessment Regulation, which began to apply to certain medicinal products this year.

89 Complete Response Letters For Unapproved Drugs, One Huge Leap For US FDA Transparency

 

The US FDA’s unprecedented publication of 89 recent CRLs for unapproved products comes with a promise to release future letters more promptly.